Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: D.Lu who wrote (117)	10/8/1998 8:11:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

Yup, looked at LJPC very closely, mostly relating to lupus and stroke/miscarriage. There are excellent research programs designed to provide pig organs that do not express the epitope responsible for antibody binding, including one at a division of Novartis (Imutran, the BTRN collaborator). There are also complement inhibitors in development. The recent description of engineered hosts and the BTRN method of absorption are alternative approaches (that I don't like). The LJPC approach is therefore rather complex and risky, IMO. Perhaps I should say rather complex and very risky..... not one chance in hell. I do not consider it to be completely crazy to be looking for passive inhibitors that interfere with the binding of antibody. If the LJPC effort points in that direction, then.... still sort of nuts, given efforts to secure pig organs that do not express the antigen. >> My intuition is that the large share orders were scooped up by the market maker,who then,working with a thin float,was able to raise the the bid and ask for us retail suckers << Don't think so. I'm preparing a brief report (general outline, technical approaches, etc...... no investment advice or rating) on BTRN for BioPlatform, Inc. If anyone is interested in it, please leave a PM for John Metcalf...... exchange2000.com